Drugs / Petrelintide
Petrelintide
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials · 1 met primary | ||||||
| Phase 1 | NCT07682818 | May 2026 → Apr 2027 expected | liver disease, severe congenital | Zealand Pharma | Recruiting | No outcome recorded |
| Phase 1 | NCT07076030 | Apr → Nov 2025 | impaired renal function disease | Zealand Pharma | Completed | No outcome recorded |
| Phase 1 | NCT05613387 | Nov 2022 → Jun 2024 | obesity disorder | Zealand Pharma | Completed | Met primary |
| Phase 1 | NCT05096598 | Oct 2021 → Jan 2023 | obesity disorder | Zealand Pharma | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT07589686 | Sep 2026 → Nov 2027 expected | obesity disorder | Hoffmann-La Roche | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06926842 | Apr 2025 → Aug 2026 overdue | obesity disorder, type 2 diabetes mellitus | Zealand Pharma | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06662539 | Dec 2024 → Sep 2025 | obesity disorder | Zealand Pharma | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07338214 Comparator | Dec 2025 → Mar 2026 | obesity disorder | Zealand Pharma | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 14
| Date | Issuer | Release |
|---|---|---|
| 2026-06-05 | Zealand Pharma | Results New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesity zealandpharma.com ↗
Results from the 42-week, Phase 2 trial show that participants who received once-weekly subcutaneous injections of petrelintide, an amylin analog, achieved clinically meaningful reductions in body weight compared to placebo. |
| 2026-06-01 | Hoffmann-La Roche | Results Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions roche.com ↗
Late-breaking data from the Phase II ZUPREME-1 trial showcase petrelintide’s efficacy, safety, and compelling tolerability profile, which has the potential to redefine the weight management experience for people living with overweight or obesity |
| 2026-05-31 | Genentech, Inc. | Results Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions gene.com ↗
Late-breaking data from the Phase II ZUPREME-1 trial showcase petrelintide’s efficacy, safety, and compelling tolerability profile, which has the potential to redefine the weight management experience for people living with overweight or obesity |
| 2026-04-23 | Hoffmann-La Roche | Results [Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc roche.com ↗
Roche announces positive phase II results for petrelintide, an amylin analogue developed for people living with overweight and obesity |
| 2026-03-05 | Zealand Pharma | Results Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity zealandpharma.com ↗
The trial met its primary endpoint, demonstrating that once-weekly subcutaneous injections of petrelintide (dose-escalated every fourth week) resulted in statistically significant and clinically meaningful reductions in body weight from baseline after 28 weeks in all five treatment arms compared to placebo. |
| 2026-03-05 | Hoffmann-La Roche | Results Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity roche.com ↗
The study met its primary endpoint, demonstrating that once-weekly subcutaneous injections of petrelintide (escalated every fourth week ) resulted in statistically significant and clinically meaningful weight loss from baseline after 28 weeks in all five treatment arms compared to placebo. |
| 2026-03-05 | Genentech, Inc. | Results Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity gene.com ↗
The study met its primary endpoint, demonstrating that once-weekly subcutaneous injections of petrelintide (escalated every fourth week ) resulted in statistically significant and clinically meaningful weight loss from baseline after 28 weeks in all five treatment arms compared to placebo. |
| 2024-08-15 | Zealand Pharma | Results Zealand Pharma Announces Financial Results for the First Half of 2024 zealandpharma.com ↗
Petrelintide was very well tolerated, with no serious or severe adverse events (AEs). |
| 2024-06-20 | Zealand Pharma | Results Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide zealandpharma.com ↗ |
| 2023-10-17 | Zealand Pharma | Results Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek zealandpharma.com ↗
In this clinical trial, low doses of ZP8396 induced reductions in body weight of up to 5.3% in healthy lean and overweight participants (mean body weight of 82 kg and BMI of 25.4) over only 6 weeks of treatment. |
| 2023-07-03 | Zealand Pharma | Results Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396 zealandpharma.com ↗
Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396 |
| 2023-06-24 | Zealand Pharma | Results Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions zealandpharma.com ↗
Body weight reductions reached up to a mean of 4.2% from baseline (4.8% placebo-corrected) within one week following a single dose of ZP8396 and were well-sustained over six weeks of observation |
| 2023-03-28 | Zealand Pharma | Results Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396 zealandpharma.com ↗
Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced Phase 1a results for ZP8396, the company’s amylin analogue. |
| 2022-05-31 | Zealand Pharma | Results Zealand Pharma Announces Multiple Presentations at the 82nd Annual American Diabetes Association Scientific Sessions, Including Initial Clinical Data on GLP-1/GLP-2 Dual Agonist Dapiglutide zealandpharma.com ↗
Zealand also has a poster presentation with preclinical data highlighting the weight loss effects of ZP8396. |
All press releases naming this drug 20 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Petrelintide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07338214 ↗ |
| Known as | Petrelintida | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314864 ↗ |
| Known as | ZP8396 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05096598 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL5314864 ↗ |
| Route | Subcutaneous | “given subcutaneously (s.c., under the skin)” NCT05096598 ↗ |